# Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants

> **NCT00257387** · PHASE1,PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 120 (—)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT00257387
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 120 (—)
- **Last updated:** 2011-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257387, "Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00257387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*